Evidence‑Based Antihypertensive Regimen Selection

Initial Drug Selection

Race‑Based Considerations

• In patients of African descent, a calcium‑channel blocker or a thiazide diuretic should be used as first‑line therapy because ACE inhibitors and ARBs have reduced efficacy as monotherapy in this population (lower renin activity). European Society of Cardiology (ESC) recommendation. 1
• In patients who are not of African descent, any of the following classes—ACE inhibitor, ARB, calcium‑channel blocker, or thiazide diuretic—may be chosen as first‑line therapy. ESC recommendation. 1
• When an ACE inhibitor or ARB is combined with a thiazide diuretic in Black patients, the inter‑racial differences in blood‑pressure reduction disappear, making the combination equally effective. ESC recommendation. 1

Age‑Based Selection

• For elderly patients (≥ 60 years) or those with isolated systolic hypertension, thiazide diuretics or calcium‑channel blockers are preferred because they provide superior stroke prevention and overall cardiovascular event reduction. ESC recommendation. [2][1]
• Aggressive antihypertensive treatment in the elderly yields substantial reductions in stroke and coronary events and is therefore appropriate despite advanced age. ESC recommendation. 2

Compelling Indications (Organ‑Specific)

Diabetes Mellitus

• ACE inhibitors or ARBs should be used as first‑line therapy in patients with diabetes. ESC recommendation. 2

Chronic Kidney Disease / Proteinuria

• ACE inhibitors or ARBs are mandatory first‑line agents to slow progression of nephropathy. ESC recommendation. 2
• When estimated glomerular filtration rate is markedly reduced, loop diuretics are preferred over thiazides. ESC recommendation. 2

Heart Failure

• The therapeutic backbone includes diuretics (thiazide or loop according to severity), beta‑blockers (carvedilol, metoprolol succinate, or bisoprolol), ACE inhibitors or ARBs, and aldosterone antagonists (spironolactone or eplerenone). ESC recommendation. 2
• Non‑dihydropyridine calcium‑channel blockers (diltiazem, verapamil) should be avoided because of negative inotropic effects. ESC recommendation. 2

Coronary Artery Disease / Post‑Myocardial Infarction

• Beta‑blockers together with ACE inhibitors (or ARBs if ACE inhibitors are not tolerated) form the foundational regimen. ESC recommendation. 2
• Beta‑blockers reduce mortality by approximately 28 % after an acute myocardial infarction. American Heart Association (AHA) evidence. 1

Angina Pectoris

• Beta‑blockers or calcium‑channel blockers are preferred agents for symptom control. ESC recommendation. 2

Atrial Fibrillation

• For recurrent atrial fibrillation, an ARB or ACE inhibitor is recommended. ESC recommendation. 2
• For permanent atrial fibrillation requiring rate control, a beta‑blocker or a non‑dihydropyridine calcium‑channel blocker may be used. ESC recommendation. 2

Left Ventricular Hypertrophy

• ACE inhibitors, calcium‑channel blockers, or ARBs are preferred because they effectively regress left ventricular hypertrophy. ESC recommendation. 2

Metabolic Syndrome

• ACE inhibitors, ARBs, or calcium‑channel blockers are preferred; beta‑blockers should be used cautiously as they may worsen glucose metabolism and lipid profiles. ESC recommendation (beta‑blocker caution) and AHA evidence for metabolic impact. [2][1]

Peripheral Artery Disease

• Calcium‑channel blockers are the preferred class. ESC recommendation. 2

Contraindications

Absolute Contraindications

• Pregnancy: ACE inhibitors and ARBs are absolutely contraindicated; alternatives include calcium‑channel blockers (e.g., nifedipine), methyldopa, or beta‑blockers (e.g., labetalol). ESC recommendation. 2
• Severe asthma or high‑grade atrioventricular block (grade 2‑3): Beta‑blockers are contraindicated. ESC recommendation. 2
• Bilateral renal‑artery stenosis: ACE inhibitors and ARBs are contraindicated. ESC recommendation. 2
• History of angioedema: ACE inhibitors are contraindicated. ESC recommendation. 2
• Gout: Thiazide diuretics are contraindicated. ESC recommendation. 2
• Renal failure or hyperkalaemia: Aldosterone antagonists (spironolactone, eplerenone) are contraindicated. ESC recommendation. 2

Relative Contraindications (Use with Caution)

• Chronic obstructive pulmonary disease: Beta‑blockers should be avoided unless a compelling indication exists; calcium‑channel blockers are safe. ESC recommendation. 2
• Metabolic syndrome or glucose intolerance: Thiazide diuretics and beta‑blockers may worsen metabolic parameters. ESC recommendation and AHA evidence. [2][1]
• Peripheral artery disease: Beta‑blockers may aggravate symptoms. ESC recommendation. 2
• Athletes / highly active individuals: Beta‑blockers may limit exercise capacity. ESC recommendation. 2

Combination Therapy

When to Initiate Combination Therapy

• In stage 2 hypertension (≥ 160/100 mmHg), start with two antihypertensive agents immediately or use a single‑pill fixed‑dose combination. AHA guideline. 1

Preferred Regimens

• First‑line dual therapy: ACE inhibitor or ARB + calcium‑channel blocker or ACE inhibitor or ARB + thiazide diuretic. ESC recommendation. 2
• Triple therapy (if dual therapy fails): ACE inhibitor or ARB + calcium‑channel blocker + thiazide diuretic. ESC recommendation. 2

Regimens to Avoid

• Combining an ACE inhibitor with an ARB should never be done because it increases adverse events (hyperkalaemia, acute kidney injury) without added cardiovascular benefit. ESC recommendation. 2
• Adding a beta‑blocker as a second or third agent is discouraged unless a compelling indication exists (e.g., angina, post‑MI, heart failure, atrial fibrillation), as beta‑blockers are less effective than calcium‑channel blockers or diuretics for stroke prevention. ESC recommendation and AHA evidence. [2][1]

Practical Pitfalls

• Do not add a beta‑blocker for uncomplicated hypertension when calcium‑channel blockers or thiazide diuretics provide superior stroke‑prevention efficacy. ESC recommendation and AHA evidence. [2][1]

Hypertension Management Guidelines

Diagnosis and Treatment Thresholds

• The American Heart Association recommends starting pharmacological treatment when systolic blood pressure (SBP) is ≥140 mmHg or diastolic blood pressure (DBP) is ≥90 mmHg with confirmed hypertension 3
• The American College of Cardiology recommends starting pharmacological treatment when SBP is 130-139 mmHg with existing cardiovascular disease 3
• The American College of Cardiology recommends starting pharmacological treatment when SBP is 130-139 mmHg with diabetes, chronic kidney disease, or high cardiovascular risk (10-year risk ≥10%) 3, 4
• The European Society of Cardiology recommends confirming diagnosis with out-of-office measurements (home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg) before initiating treatment 5

Initial Medication Selection

• For Black patients, the American Heart Association recommends starting with a calcium channel blocker (CCB) or thiazide diuretic 5, 6
• For non-Black patients, the American College of Cardiology recommends starting with an ACE inhibitor, ARB, CCB, or thiazide diuretic 3, 4
• The American Heart Association recommends preferring ACE inhibitor or ARB as first-line for patients with diabetes mellitus or chronic kidney disease 3, 4

Special Populations

• For patients with diabetes mellitus, the American Diabetes Association recommends targeting blood pressure <130/80 mmHg 3
• For patients with chronic kidney disease, the National Kidney Foundation recommends targeting blood pressure <130/80 mmHg 3, 4
• For patients with heart failure, the American College of Cardiology recommends avoiding non-dihydropyridine CCBs (diltiazem, verapamil) 6

Blood Pressure Targets

• The American Heart Association recommends a standard target of <140/90 mmHg for all patients 3
• The American College of Cardiology recommends intensive targets (<130/80 mmHg) for patients with existing cardiovascular disease, diabetes mellitus, chronic kidney disease, or high cardiovascular risk (10-year risk ≥10%) 3, 4

Monitoring Schedule

• The American Heart Association recommends monthly follow-up after initiation or medication change until target is achieved 3
• The American College of Cardiology recommends checking serum potassium and creatinine at baseline, 2-4 weeks after starting or dose change, and annually if stable 5, 6

Critical Pitfalls to Avoid

• The American Heart Association recommends never combining ACE inhibitor + ARB (increases adverse events without benefit) 3, 4, 6
• The American College of Cardiology recommends never using non-dihydropyridine CCBs (diltiazem, verapamil) in heart failure 6
• The American Heart Association recommends never delaying treatment intensification—most patients require 2-3 medications to achieve target 3